Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Share-based Compensation (2020 - 2025)

Maxcyte (MXCT) has disclosed Share-based Compensation for 6 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 42.02% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.6 million, a 13.92% decrease, with the full-year FY2024 number at $13.1 million, down 6.41% from a year prior.
  • Share-based Compensation was $2.0 million for Q3 2025 at Maxcyte, down from $3.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.6 million in Q3 2023 to a low of $1.3 million in Q1 2021.
  • A 5-year average of $2.9 million and a median of $3.1 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 282.17% in 2021, then tumbled 42.02% in 2025.
  • Maxcyte's Share-based Compensation stood at $2.4 million in 2021, then rose by 27.36% to $3.1 million in 2022, then rose by 14.62% to $3.6 million in 2023, then fell by 12.31% to $3.1 million in 2024, then tumbled by 37.65% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Share-based Compensation are $2.0 million (Q3 2025), $3.5 million (Q2 2025), and $3.0 million (Q1 2025).